Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net income	$ 160,687	$ 30,428
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13,344	13,873
Acquired in-process research & development	0	115,490
Bad debt expense (recoveries)	85	(27)
Stock-based compensation	29,376	28,357
Write-down of inventory and other	7,110	6,195
Accretion on marketable securities	319	1,768
Change in fair value of other investments	(77,373)	(22,440)
Gain on previously held interest in preCARDIA	0	(20,980)
Deferred tax provision	(7,416)	8,193
Change in fair value of contingent consideration	(6,515)	108
Other non-cash operating activities	1,556	1,553
Changes in assets and liabilities:
Accounts receivable	(6,402)	7,444
Inventories	(18,346)	(11,673)
Prepaid expenses and other assets	(13,149)	(20,300)
Accounts payable	1,570	(6,266)
Accrued expenses and other liabilities	(3,408)	(15,590)
Deferred revenue	86	(202)
Net cash provided by operating activities	81,524	115,931
Investing activities:
Purchases of marketable securities	(272,618)	(333,832)
Proceeds from the sale and maturity of marketable securities and other	359,671	326,518
Purchases of other investments	(4,975)	(3,866)
Proceeds from sales of Shockwave Medical securities	39,995
Purchases of property and equipment	(12,392)	(14,394)
Net cash provided by (used for) investing activities	109,681	(108,395)
Financing activities:
Proceeds from the exercise of stock options	1,999	8,382
Taxes paid related to net share settlement upon vesting of stock awards	(12,802)	(12,129)
Repurchase of common stock	(126,623)	0
Proceeds from the issuance of stock under employee stock purchase plan	3,308	2,961
Net cash used for financing activities	(134,118)	(786)
Effect of exchange rate changes on cash and cash equivalents	(7,570)	2,422
Net increase in cash and cash equivalents	49,517	9,172
Cash and cash equivalents at beginning of period	132,818	232,710
Cash and cash equivalents at end of period	182,335	241,882
Supplemental disclosure of cash flow information:
Cash paid for income taxes, net of refunds	68,615	35,642
Supplemental disclosure of non-cash activities:
Property and equipment in accounts payable and accrued expenses	1,427	578
Right-of-use assets obtained in exchange for lease liabilities	356	569
Precardia
Investing activities:
Payments for acquisition	$ 0	$ (82,821)